Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
31.81
+3.60 (+12.76%)
Streaming Delayed Price
Updated: 10:06 AM EDT, May 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,375,465
Open
29.60
Bid (Size)
31.78 (200)
Ask (Size)
31.84 (500)
Prev. Close
28.21
Today's Range
29.35 - 32.00
52wk Range
10.58 - 30.33
Shares Outstanding
692,072,184
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Roivant Sciences Q4 Earnings Call Highlights
↗
Today 10:07 EDT
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...
Via
MarketBeat
Topics
Earnings
Government
Stay updated with the stocks that are on the move in today's pre-market session.
↗
Today 8:30 EDT
Via
Chartmill
Performance
YTD
+45.1%
+45.1%
1 Month
+9.4%
+9.4%
3 Month
+17.4%
+17.4%
6 Month
+55.0%
+55.0%
1 Year
+193.5%
+193.5%
More News
Read More
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Today 7:00 EDT
From
Roivant Sciences
Via
GlobeNewswire
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
↗
May 18, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings
↗
May 14, 2026
Via
Chartmill
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
↗
May 18, 2026
Via
The Motley Fool
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
↗
May 18, 2026
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
↗
May 16, 2026
Via
The Motley Fool
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
Via
MarketMinute
Topics
Intellectual Property
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026
From
Roivant Sciences
Via
GlobeNewswire
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
↗
March 15, 2026
Via
The Motley Fool
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
↗
March 04, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock
↗
March 04, 2026
Via
Stocktwits
Topics
Intellectual Property
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row
↗
March 03, 2026
Via
Stocktwits
Topics
Intellectual Property
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
March 03, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
March 03, 2026
From
Roivant Sciences
Via
GlobeNewswire
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential
↗
February 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth
↗
February 13, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Supply Chain
Frequently Asked Questions
Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 31.81
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 05/20/26 10:06 AM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 22.01B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 22B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.